LU92033I2 - Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) - Google Patents

Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)

Info

Publication number: LU92033I2
Authority: LU; Luxembourg
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

LU92033C

Other languages

English (en)

Other versions

LU92033I9 (fr

Original Assignee

Genzyme Global S A R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2012-06-27

Publication date

2012-08-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-27 Application filed by Genzyme Global S A R L filed Critical Genzyme Global S A R L

2012-08-27 Publication of LU92033I2 publication Critical patent/LU92033I2/fr

2019-01-03 Publication of LU92033I9 publication Critical patent/LU92033I9/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LU92033C 2001-07-31 2012-06-27 Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) LU92033I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
PCT/US2002/024212 WO2003011277A2 (fr)	2001-07-31	2002-07-30	Methodes de mobilisation de cellules souches/embryonnaires

Publications (2)

Publication Number	Publication Date
LU92033I2 true LU92033I2 (fr)	2012-08-27
LU92033I9 LU92033I9 (fr)	2019-01-03

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92033C LU92033I2 (fr)	2001-07-31	2012-06-27	Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Country Status (28)

Country	Link
US (9)	US6987102B2 (fr)
EP (3)	EP1411918B1 (fr)
JP (2)	JP5137288B2 (fr)
KR (2)	KR100996378B1 (fr)
CN (2)	CN102302493B (fr)
AT (1)	ATE538785T1 (fr)
AU (1)	AU2002318927B2 (fr)
BE (1)	BE2019C544I2 (fr)
BR (1)	BRPI0211570B8 (fr)
CA (1)	CA2455559C (fr)
CY (4)	CY1112633T1 (fr)
DK (2)	DK2371361T3 (fr)
ES (2)	ES2742730T3 (fr)
FR (2)	FR12C0042I1 (fr)
HU (1)	HUP0402360A2 (fr)
IL (2)	IL159312A0 (fr)
LT (2)	LT2371361T (fr)
LU (2)	LU92033I2 (fr)
MX (1)	MXPA04000982A (fr)
NL (2)	NL300537I2 (fr)
NO (4)	NO336989B1 (fr)
NZ (1)	NZ530169A (fr)
PL (1)	PL364673A1 (fr)
PT (2)	PT1411918E (fr)
RU (1)	RU2309741C2 (fr)
SI (2)	SI2371361T1 (fr)
WO (1)	WO2003011277A2 (fr)
ZA (1)	ZA200400658B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1411918E (pt) *	2001-07-31	2012-03-06	Genzyme Global S A R L	Métodos para mobilizar células progenitoras/estaminais
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
HUP0402458A2 (hu)	2001-12-21	2005-07-28	Anormed Inc.	Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
JP4667241B2 (ja) *	2003-06-27	2011-04-06	旭化成株式会社	細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株
WO2005002522A2 (fr) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions et methodes pour traiter une ischemie tissulaire
US7417026B2 (en)	2003-08-13	2008-08-26	Children's Hospital Medical Center	Mobilization of hematopoietic cells
EP1656451A2 (fr)	2003-08-13	2006-05-17	Children's Hospital Medical Center	Peptides chimeriques pour regulation de gtpases
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (fr) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
EP1796716A4 (fr) *	2004-08-13	2010-09-08	Anormed Inc	Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
EP1814587A2 (fr) *	2004-11-05	2007-08-08	The General Hospital Corporation	Eloignement volontaire de cellules migratoires humaines d'une source d'agents
MX2007015834A (es)	2005-06-13	2008-09-15	Cleveland Biolabs Inc	Metodos de proteccion contra apoptosis utilizando polipeptidos.
AU2006280945A1 (en) *	2005-08-19	2007-02-22	Genzyme Corporation	Methods to enhance chemotherapy
WO2007025166A2 (fr) *	2005-08-25	2007-03-01	Repair Technologies, Inc.	Dispositifs, compositions et methodes de protection et de reparation de cellules et de tissus
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
JP2009527552A (ja) *	2006-02-24	2009-07-30	ジェンザイム・コーポレーション	血流の増加および組織再生の促進またはそのいずれかのための方法
WO2007108689A2 (fr) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Nouveau procede d'induction de la differenciation de cellules souches et progenitrices
RU2009108289A (ru) *	2006-08-07	2010-09-20	Джензим Корпорейшн (Us)	Комбинированная терапия
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (fr) *	2008-08-29	2010-03-04	Genzyme Corporation	Antagonistes du cxcr4 pour des lésions rénales
US20130039882A1 (en) *	2009-10-28	2013-02-14	Henry Ford Health System	Method to mitigate injury from radiation exposure
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
WO2012019168A2 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucléiques modifiés et leurs procédés d'utilisation
JP2014513727A (ja)	2011-05-16	2014-06-05	ジェンザイム・コーポレーション	Ｃｘｃｒ４拮抗薬の使用
WO2014152629A1 (fr) *	2013-03-15	2014-09-25	Miller Leonard B	Traitement combiné pour améliorer la cicatrisation de tissu mou, la cicatrisation de greffe de tissu adipeux, la cicatrisation osseuse endochondrale et l'ostéointégration
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
AU2016324160A1 (en)	2015-09-18	2018-04-26	The General Hospital Corporation Dba Massachusetts General Hospital	Localized delivery of anti-fugetactic agent for treatment of cancer
EP3389652B1 (fr)	2015-12-14	2022-09-28	X4 Pharmaceuticals, Inc.	Méthodes de traitement du cancer
CA3008272A1 (fr)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methodes de traitement du cancer
US11433136B2 (en)	2015-12-18	2022-09-06	The General Hospital Corporation	Polyacetal polymers, conjugates, particles and uses thereof
JP7055380B2 (ja)	2015-12-22	2022-04-18	エックス４ファーマシューティカルズ，インコーポレイテッド	免疫不全疾患を処置するための方法
EP3440112A4 (fr)	2016-04-08	2019-10-09	X4 Pharmaceuticals, Inc.	Méthodes de traitement du cancer
WO2017216373A1 (fr) *	2016-06-16	2017-12-21	Centre National De La Recherche Scientifique	Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
WO2017223229A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
CA3027500A1 (fr)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
JP7054529B2 (ja)	2016-06-21	2022-04-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
US11453706B2 (en)	2016-09-09	2022-09-27	The General Hospital Corporation	HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
JP2019534249A (ja)	2016-09-09	2019-11-28	ザジェネラルホスピタルコーポレイション	癌の治療のための抗化学忌避剤とのｈｓｐ融合タンパク質
US11364264B2 (en)	2016-09-09	2022-06-21	The General Hospital Corporation	Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018106738A1 (fr)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2020005878A (es) *	2017-12-06	2020-10-07	Magenta Therapeutics Inc	Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas.
US10709763B2 (en) *	2017-12-19	2020-07-14	Gpcr Therapeutics, Inc.	GPCR heteromer inhibitors and uses thereof
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en)	2019-10-08	2024-08-13	The Regents Of The University Of California	Methods and compositions for hematopoietic stem cell mobilization
CN115515585A (zh)	2020-03-10	2022-12-23	X4 制药有限公司	用于治疗中性粒细胞减少症的方法
EP4146797A1 (fr)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Traitement pour les maladies neurodégénératives
JP2024536246A (ja)	2021-10-01	2024-10-04	ヤンセンファーマシューティカエヌ．ベー．	前駆細胞産生を増加させる方法
CN118987175A (zh) *	2024-08-13	2024-11-22	广东壹加再生医学研究院有限公司	普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) *	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
ATE166864T1 (de)	1989-10-23	1998-06-15	Nycomed Salutar Inc	Mehrzähnige metall-chelatierende verbindungen
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
US5021409A (en)	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
FR2672051B1 (fr) *	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en) *	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
JP3731892B2 (ja)	1992-11-13	2006-01-05	ボードオブリージェンツオブユニバーシティオブワシントン	造血幹細胞の末梢化
GB9400411D0 (en) *	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) *	1995-02-02	1995-03-22	Abuljadayel Ilham M S	A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) *	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) *	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
GB9511357D0 (en)	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (fr) *	2000-05-09	2001-11-09	The University Of British Columbia	Traitement antagoniste cxcr4 de cellules hematopoietiques
DE1068357T1 (de) *	1998-03-30	2001-07-19	Northwest Biotherapeutics, Inc.	Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
AU4696899A (en) *	1998-06-19	2000-01-05	General Hospital Corporation, The	Modulating platelet function
CA2244554A1 (fr) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition d'une greffe par rapport a la maladie d'un hote
EP1117762A4 (fr)	1998-09-29	2004-02-25	Gamida Cell Ltd	Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
ATE315390T1 (de) *	1998-11-17	2006-02-15	Smithkline Beecham Corp	Zyklische polyamine zur behandlung der thrombozytopenie
EP1016413A1 (fr)	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
BR0010655A (pt)	1999-03-24	2002-02-13	Anormed Inc	Compostos heterocìclicos para ligação ao receptor de quimiocina
WO2000066112A1 (fr) *	1999-05-03	2000-11-09	Smithkline Beecham Corporation	Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
CN100335478C (zh) *	1999-12-17	2007-09-05	阿诺麦德股份有限公司	结合趋化因子受体的杂环化合物
EP1286684B1 (fr)	2000-05-09	2004-04-28	The University Of British Columbia	Utilisation d'antagonistes du cxcr4 pour traiter les maladies autoimmunes et le cancer
EP1290033B1 (fr) *	2000-06-05	2012-10-31	The Trustees of Columbia University in the City of New York	Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
US6734191B2 (en)	2000-09-15	2004-05-11	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
JP2004508422A (ja)	2000-09-15	2004-03-18	アノーメッド　インコーポレイティド	ケモカインレセプタ結合複素環式化合物
SG126006A1 (en)	2000-09-15	2006-10-30	Anormed Inc	Chemokine receptor binding heterocyclic compounds
EP1322626B1 (fr)	2000-09-29	2008-11-05	Anormed Inc.	Procede de preparation de polyamines cycliques a protection n-1 comportant n azotes sur leur noyau, et produits associes
CN1264498C (zh)	2001-01-23	2006-07-19	P&G克莱罗尔公司	用于氧化性染发的主要中间体
PT1411918E (pt) *	2001-07-31	2012-03-06	Genzyme Global S A R L	Métodos para mobilizar células progenitoras/estaminais
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
HUP0402458A2 (hu)	2001-12-21	2005-07-28	Anormed Inc.	Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 CA CA2455559A patent/CA2455559C/fr not_active Expired - Lifetime
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 EP EP02750370A patent/EP1411918B1/fr not_active Revoked
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko not_active Expired - Lifetime
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/fr not_active Revoked
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/fr active Search and Examination
- 2002-07-30 BR BRPI0211570 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/fr not_active Withdrawn
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Ceased
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en not_active Expired - Lifetime
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I2/el unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I2/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
EP2371361A1 (fr)	2011-10-05
US20110129448A1 (en)	2011-06-02
PT2371361T (pt)	2019-09-10
CN1561208A (zh)	2005-01-05
RU2309741C2 (ru)	2007-11-10
AU2002318927B2 (en)	2007-01-04
LU92033I9 (fr)	2019-01-03
PL364673A1 (en)	2004-12-13
LTPA2019018I1 (lt)	2019-12-10
NL301031I2 (nl)	2020-07-20
HUP0402360A2 (hu)	2005-02-28
CA2455559A1 (fr)	2003-02-13
BR0211570A (pt)	2004-07-13
CY2019038I1 (el)	2020-05-29
US7935692B2 (en)	2011-05-03
JP2004538303A (ja)	2004-12-24
US6987102B2 (en)	2006-01-17
US20150246019A1 (en)	2015-09-03
LTC2371361I2 (lt)	2021-09-27
US20190216773A1 (en)	2019-07-18
FR19C1058I2 (fr)	2020-10-23
MXPA04000982A (es)	2004-04-20
NZ530169A (en)	2007-04-27
KR100996378B1 (ko)	2010-11-25
WO2003011277A3 (fr)	2003-05-22
CN102302493A (zh)	2012-01-04
EP1411918A4 (fr)	2007-11-14
NO20040407L (no)	2004-03-19
US20030130250A1 (en)	2003-07-10
ES2380009T3 (es)	2012-05-07
EP3632425A1 (fr)	2020-04-08
CA2455559C (fr)	2012-01-10
US20080063624A1 (en)	2008-03-13
EP1411918A2 (fr)	2004-04-28
EP2371361B1 (fr)	2019-08-07
NO2020003I1 (no)	2020-03-05
RU2004105961A (ru)	2005-03-20
NL301031I1 (nl)	2020-02-05
SI1411918T1 (sl)	2012-04-30
BRPI0211570B1 (pt)	2020-01-28
IL159312A (en)	2015-05-31
KR20040020075A (ko)	2004-03-06
LT2371361T (lt)	2019-09-10
DK1411918T3 (da)	2012-04-23
LUC00139I1 (fr)	2019-11-27
US20060193826A1 (en)	2006-08-31
NO20150674A1 (no)	2015-05-27
SI2371361T1 (sl)	2019-10-30
KR20090130152A (ko)	2009-12-17
ZA200400658B (en)	2005-07-27
LUC00139I2 (fr)	2021-02-10
US20060223180A1 (en)	2006-10-05
US7897590B2 (en)	2011-03-01
HK1063005A1 (en)	2004-12-10
NL300537I2 (fr)	2017-02-02
US20170049747A1 (en)	2017-02-23
CY2019038I2 (el)	2020-05-29
JP2008195730A (ja)	2008-08-28
FR19C1058I1 (fr)	2019-11-22
BE2019C544I2 (fr)	2021-07-19
WO2003011277A2 (fr)	2003-02-13
NO336989B1 (no)	2015-12-14
US20130273009A1 (en)	2013-10-17
CN102302493B (zh)	2015-08-12
NO344632B1 (no)	2020-02-17
CY1112633T1 (el)	2015-08-05
IL159312A0 (en)	2004-06-01
EP1411918B1 (fr)	2011-12-28
NO2016011I1 (no)	2016-06-10
CY2012017I1 (el)	2015-08-05
CY2012017I2 (el)	2015-08-05
DK2371361T3 (da)	2019-08-19
ES2742730T3 (es)	2020-02-17
PT1411918E (pt)	2012-03-06
ATE538785T1 (de)	2012-01-15
CY1122199T1 (el)	2020-05-29
CN1561208B (zh)	2010-11-10
JP5137288B2 (ja)	2013-02-06
BRPI0211570B8 (pt)	2021-05-25
FR12C0042I1 (fr)	2012-08-10

Publication	Publication Date	Title
LTC2371361I2 (lt)	2021-09-27	Pirmtakų/kamieninių ląstelių suaktyvinimo būdai
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
MXPA05003193A (es)	2005-06-08	Compuesto de adenina novedoso y uso del mismo.
HUP0004259A2 (hu)	2001-04-28	VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR880005093A (ko)	1988-06-28	5-알킬벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 약제학적 조성물
ES2164164T3 (es)	2002-02-16	Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
KR920012082A (ko)	1992-07-25	Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
ES8800936A1 (es)	1987-12-01	Un procedimiento para la obtencion de derivados de bi- y triciclicos de piridona
ES2262504T3 (es)	2006-12-01	Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.
MA27576A1 (fr)	2005-10-03	Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT1209166E (pt)	2004-06-30	Novos derivados de a-500359
OA09239A (fr)	1992-06-30	"Nouveaux céphèmes et procédés pour leur préparation".
WO2007106063A3 (fr)	2007-12-21	Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu
EA200101050A1 (ru)	2002-04-25	Замещенные бензолактамные соединения
EA200000527A2 (ru)	2000-12-25	Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
ATE228134T1 (de)	2002-12-15	Kondensierte pyrimidinderivate und diese enthaltende pharmazeutische zubereitungen
EA200001157A3 (ru)	2001-08-27	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
FR2823749B1 (fr)	2004-02-20	Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant